Liver Transplantation for HCC: A Review

Indian Journal of Surgery

Volumn 74, Issue 1, 2012, Pages 100-117

  Kakodkar, Rahul ^a   Soin, A S ^a  

^a Institute of Liver Transplantation and Regenerative Medicine   (India)

Author keywords

Alpha fetoprotein; Chemoembolization; Hepatocellular carcinoma; Liver transplantation; Living donor; Microvascular invasion; Milan criteria; Radiofrequency ablation

Indexed keywords

EID: 84855938580     PISSN: 09722068     EISSN: 09739793     Source Type: Journal    
DOI: 10.1007/s12262-011-0387-2     Document Type: Review

References (141)

1. Bosch FX, Ribes J, Díaz M, Cléries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(Suppl 1): S5-S16.
2. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
3. Jemal A et al (2010) Global patterns of cancer incidence and mortality rates and trends. Canc Epidemiol Biomarkers Prev 19: 1893-1907.
4. Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, Toyota T, Takahashi T, Kasukawa R (2000) Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 95(4): 1036-1040.
5. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42: 1208-1236.
6. Llovet JM, Fuster J, Bruix J (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30: 1434-1440.
7. Okada S, Shimada K, Yamamoto J, Takayama T, KosugeT YS et al (1994) Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 106: 1618-1624.
8. Minagawa M, Makuuchi M, Takayama T, Kokudo N (2003) Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 238: 703-710.
9. Poon RT, Fan ST, Lo CM, Liu CL, Wong J (1999) Intrahepaticrecurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 229: 216-222.
10. Adachi E, Maeda T, Matsumata T, Shirabe K, Kinukawa N, Sugimachi K, Tsuneyoshi M (1995) Risk factors for intrahepaticrecurrence in human small hepatocellular carcinoma. Gastroenterology 108: 768-775.
11. Wong R, Frenette C, Gish R (2011) Hepatocellular carcinoma: locoregional and targeted therapies. Gastroenterol Clin North Am 40(3): 599-610.
12. Starzl TE, Porter KA, Brettschneider L, Penn I, Bell P, Putnam CW, McGuire RL (1969) Clinical and pathologic observations after orthotopic transplantation of the human liver. Surg Gynecol Obstet 128(2): 327-339.
13. Penn I (1991) Hepatic transplantation for primary and metastasis cancer of the liver. Surgery 110: 726-735.
14. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A (1993) Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 218(2): 145-151.
15. Mazzaferro V, Regalia E, Doci R, Andreola S, PulvirentiA BF et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334: 693-699.
16. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33(6): 1394-1403.
17. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, van Hoek B, Majno P, Metroticket Investigator Study Group (2009) Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective exploratory analysis. Lancet Oncol 10(1): 35-43.
18. Freeman RB, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R (2004) Results of the first year of the new liver allocation plan. Liver Transpl 10: 7-15.
19. Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez-Luna H, Byrne T et al (2004) Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl 10: 36-41.
20. Miller CM (2008) Ethical dimensions of living donation: experience with living liver donation. Transplant Rev (Orlando) 22: 206-209.
21. Singer PA, Lantos JD, Whitington PF, Broelsch CE, Siegler M (1988) Equipoise and the ethics of segmental liver transplantation. Clin Res 36(6): 539-545.
22. Todo S, Furukawa H, Japanese Study Group on Organ Transplantation (2004) Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 240(3): 451-459, discussion 459-461.
23. Hwang S, Lee SG, Joh JW, Suh KS, Kim DG (2005) Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 11(10): 1265-1272.
24. Pomfret EA, Lodge JP, Villamil FG, Siegler ML (2011) Should we use living donor grafts for patients with hepatocellular carcinoma? ethical considerations. Liver Transpl 17(Suppl 2): S128-S132.
25. Dvorchik I, Schwartz M, Fiel MI, Finkelstein SD, Marsh JW (2008) Fractional allelic imbalance could allow for the development of an equitable transplant selection policy for patients with hepatocellular carcinoma. Liver Transpl 14(4): 443-450.
26. Tamura S, Kato T, Berho M, Misiakos EP, O'Brien C, Reddy KR, Nery JR, Burke GW, Schiff ER, Miller J, Tzakis AG (2001) Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 136(1): 25-30, discussion 31.
27. Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, Settmacher U, Neuhaus P (2001) Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 33(5): 1080-1086.
28. Roayaie S, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, Sung M et al (2002) Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 235: 533-539.
29. Marsh JW, Dvorchik I (2003) Liver organ allocation for hepatocellular carcinoma: are we sure? Liver Transpl 9: 693-696.
30. Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, Mariani L (2011) Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 17(Suppl 2): S44-S57.
31. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP (2007) Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 7(11): 2587-2596.
32. Decaens T, Roudot-Thoraval F, Hadni-Bresson S, MeyerC GJ, Durand F et al (2006) Impact of UCSF criteria according to pre and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 12: 1761-1769.
33. D'Amico F, Schwartz M, Vitale A, Tabrizian P, Roayaie S, Thung S, Guido M, del Rio MJ, Schiano T, Cillo U (2009) Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl 15(10): 1278-1287.
34. Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, Ko GY, Park KM, Ha TY, Song GW (2008) Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 14(7): 935-945.
35. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, Liang TB, Wu LM (2008) Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 85(12): 1726-1732.
36. Prasad KR, Young RS, Burra P, Zheng SS, Mazzaferro V, Bog Moon D, Freeman RB (2011) Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transpl 17(Supp l 2): S81-S89.
37. Volk ML, Vijan S, Marrero JA (2008) A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 8: 839-846.
38. Vitale A, Volk ML, Gambato M, Zanus G, D'Amico F, Carraro A et al (2010) Estimation of the harm to the waiting list as a crucial factor in the selection of patients with hepatocellular carcinoma for liver transplantation. Transplant Proc 42: 1194-1196.
39. Broelsch CE, Frilling A, Malago M (2005) Should we expand the criteria for liver transplantation for hepatocellular carcinoma-yes, of course? J Hepatol 43: 569-573.
40. Freeman RB, Mithoefer A, Ruthazer R, Nguyen K, Schore A, Harper A, Edwards E (2006) Optimizing staging for hepatocellular carcinoma before liver transplantation: a retrospective analysis of the UNOS/OPTN database. Liver Transpl 12: 1504-1511.
41. Luca A, Caruso S, Milazzo M, Mamone G, Marrone G, Miraglia R et al (2010) Multidetector-row computed tomography (MDCT) for the diagnosis of hepatocellular carcinoma in cirrhotic candidates for liver transplantation: prevalence of radiological vascular patterns and histological correlation with liver explants. Eur Radiol 20: 898-907.
42. Sangiovanni A, Manini MA, Iavarone M, Romeo R, Forzenigo LV, Fraquelli M et al (2010) The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 59: 638-644.
43. Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, Duca P (2006) Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 101: 513-523.
44. 18F-FDGPET in liver transplantation for hepatocellular carcinoma. J Nucl Med 50: 682-687.
45. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant 9: 592-600.
46. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 44: 213-221.
47. Ho CL, Chen S, Yeung DW, Cheng TK (2007) Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 48: 902-909.
48. Wiesner RH, Freeman RB, Mulligan DC (2004) Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology 127(suppl 1): S261-S267.
49. Compagnon P, Grandadam S, Lorho R, Turlin B, Camus C, Jianrong Y et al (2008) Liver transplantation for hepatocellularcarcinoma without preoperative tumor biopsy. Transplantation 86: 1068-1076.
50. Caturelli E, Bisceglia M, Fusilli S, Squillante MM, Castelvetere M, Siena DA (1996) Cytological vs. microhistological diagnosis of hepatocellular carcinoma: comparative accuracies in the same fine-needle biopsy specimen. Dig Dis Sci 41: 2326-2331.
51. Caturelli E, Solmi L, Anti M, Fusilli S, Roselli P, Andriulli A et al (2004) Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. Gut 53: 1356-1362.
52. Durand F, Regimbeau JM, Belghiti J, Sauvanet A, Vilgrain V, Terris B et al (2001) Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol 35: 254-258.
53. Müllhaupt B, Durand F, Roskams T, Dutkowski P, Heim M (2011) Is tumor biopsy necessary? Liver Transpl 17(Suppl 2): S14-S25.
54. Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF (2008) Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 57: 1592-1596.
55. Maturen KE, Nghiem HV, Marrero JA, Hussain HK, Higgins EG, Fox GA, Francis IR (2006) Lack of tumor seeding of hepatocellular carcinoma after percutaneous needle biopsy using coaxial cutting needle technique. AJR Am J Roentgenol 187: 1184-1187.
56. Germani G, Pleguezuelo M, Stigliano R, Burroughs AK (2009) Risk of seeding is reduced by associating diagnostic biopsy with percutaneous ablation for hepatocellular carcinoma. Gut 58: 734-735.
57. Germani G, Gurusamy K, Garcovich M, Toso C, Fede G, Hemming A, Suh KS, Weber A, Kenneth Burroughs A (2011) Which matters most: number of tumors, size of the largest tumor, or total tumor volume? Liver Transpl 17(Suppl 2): S58-S66.
58. Gouw AS, Balabaud C, Kusano H, Todo S, Ichida T, Kojiro M (2011) Markers for microvascular invasion in hepatocellular carcinoma: where do we stand? Liver Transpl 17(Suppl 2): S72-S80.
59. Lee HH, Joh JW, Park JH, Lee KW, Heo JS, Choi SH, Kim SJ, Lee SK (2005) Microvascular tumor embolism: independent prognostic factor after liver transplantation in hepatocellular carcinoma. Transplant Proc 37(2): 1251-1253.
60. Esnaola NF, Lauwers GY, Mirza NQ, Nagorney DM, Doherty D, Ikai I, Yamaoka Y, Regimbeau JM, Belghiti J, Curley SA, Ellis LM, Vauthey JN (2002) Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg 6(2): 224-232, discussion 232.
61. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A et al (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359: 1995-2004.
62. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H et al (2008) EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68: 1451-1461.
63. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY et al (2009) EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136: 1012-1024.
64. Boyault S, Rickman DS, de Reyniés A, Balabaud C, Rebouissou S, Jeannot E et al (2007) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45: 42-52.
65. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S et al (2009) MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361: 1437-1447.
66. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA et al (2006) Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on aunique immune response signature of the liver microenvironment. Canc Cell 10: 99-111.
67. Llovet JM, Peña C, Shan M, Lathia C, Bruix J (2008) Biomarkers predicting outcome of patients with advanced hepatocellular carcinoma (HCC) randomized in the phase III SHARP trial. Paper presented at: 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31-November 4, 2008; San Francisco, CA.
68. Parfitt JR, Marotta P, Alghamdi M, Wall W, Khakhar A, Suskin NG et al (2007) Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl 13: 543-551.
69. Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I et al (2005) Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 11: 1086-1092.
70. Sumie S, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N et al (2008) Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol 15: 1375-1382.
71. Shirabe K, Aishima S, Taketomi A, Soejima Y, Uchiyama H, Kayashima H et al (2011) Prognostic importance of the gross classification of hepatocellular carcinoma in living donor-related liver transplantation. Br J Surg 98: 261-267.
72. Fujiki M, Takada Y, Ogura Y, Oike F, Kaido T, Teramukai S, Uemoto S (2009) Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation or hepatocellular carcinoma. Am J Transplant 9: 2362-2371.
73. Cherqui D, Boudjema K, Celebic A, Laurent A, Roudot-Thoraval F (2006) Résection hépatique pour carcinome hépatocellulaire sur foie sain et pathologique en France. Résultats de l'enquête AFC sur la période 1990-2005. In: Boudjema K, Cherqui D (eds) Cancer Hépatocellulaire. Wolters Kluwer, Rueil-Malmaison, pp 183-218.
74. Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, KochM BMW, Weitz J (2011) Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 253: 453-469.
75. Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M (2010) Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis 42: 341-347.
76. Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunvén P et al (1990) Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 107: 521-527.
77. Torzilli G, Montorsi M, Del Fabbro D, Palmisano A, Donadon M, Makuuchi M (2006) Ultrasonographically guided surgical approach to liver tumours involving the hepatic veins close to the caval confluence. Br J Surg 93: 1238-1246.
78. Kokudo N, Makuuchi M (2004) Current role of portal vein embolization/hepatic artery chemoembolization. Surg Clin North Am 84: 643-657.
79. Kishi Y, Abdalla EK, Chun YS, Zorzi D, Madoff DC, Wallace MJ et al (2009) Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg 250: 540-548.
80. Mergental H, Porte RJ (2010) Liver transplantation for unresectable hepatocellular carcinoma in patients without liver cirrhosis. Transpl Int 23: 662-667.
81. Mergental H, Adam R, Kalicinski P, Ericzon BG, Friman S, Köningsrainer A et al (2007) Liver transplantation for hepatocellular carcinoma in non-cirrhotic livers [abstract]. Liver Transpl 13(suppl 1): S119.
82. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y et al (2005) Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol 100: 1764-1771.
83. The Cancer of the Liver Italian Program(CLIP) investigators (2000) Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 31: 840-845.
84. Llovet JM, Brú C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19: 329-338.
85. Shiina S, Teratani T, Obi S et al (2005) A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129: 122-130.
86. Lin SM, Lin CJ, Lin CC et al (2004) Radiofrequency ablation improves prognosis compared to ethanol injection for hepatocellular carcinoma ≤4 cm. Gastroenterology 127: 1714-1723.
87. Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171.
88. Llovet JM, Real MI, Montana X et al (2002) Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359: 1734-1739.
89. Majno PE, Adam R, Bismuth H et al (2004) Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 239: 150-159.
90. Roayaie S, Frischer JS, Emre SH et al (2002) Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 235: 533-539.
91. Yao FY, Hirose R, Laberge J et al (2005) A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 11: 1505-1514.
92. Yao FY, Kerlan R, Davern TJ et al (2007) Excellent long-term outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis [abstract]. Hepatology 46(Suppl): 309A.
93. De Luna W, Sze DY, Ahmed A, Ha BY, Ayoub W, Keeffe EB, Cooper A, Esquivel C, Nguyen MH (2009) Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant 9(5): 1158-1168.
94. Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, Samuel D, Bismuth H (2003) Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg 238(4): 508-518, discussion 518-519.
95. Poon RT, Fan ST, Lo CM, Liu CL, Wong J (2002) Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 235(3): 373-382.
96. Cherqui D, Laurent A, Mocellin N, Tayar C, Luciani A, van Nhieu JT, Decaens T, Hurtova M, Memeo R, Mallat A, Duvoux C (2009) Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg 250(5): 738-746.
97. Panaro F, Piardi T, Cag M, Cinqualbre J, Wolf P, Audet M (2011) Robotic liver resection as a bridge to liver transplantation. JSLS 15(1): 86-89.
98. Landman MP, Feurer ID, Pinson CW, Moore DE (2011) Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria? HPB (Oxford) 13(11): 783-791.
99. Huo TI, Huang YH, Su CW, Lin HC, Chiang JH, Chiou YY et al (2008) Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy. Clin Transplant 22: 469-475.
100. Yao FY, Bass NM, Nikolai B, Merriman R, Davern TJ, Kerlan R et al (2003) A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 9: 684-692.
101. Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E et al (2002) Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 50: 123-128.
102. Aloia TA, Adam R, Samuel D, Azoulay D, Castaing D (2007) A decision analysis model identifies the interval of efficacy for transarterial chemoembolization (TACE) in cirrhotic patients with hepatocellular carcinoma awaiting liver transplantation. J Gastrointest Surg 11: 1328-1332.
103. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK et al (2011) Radioembolization results in longer time-to progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140: 497-507.
104. Majno P, Lencioni R, Mornex F, Girard N, Poon RT, Cherqui D (2011) Is the treatment of hepatocellular carcinoma on the waiting list necessary? Liver Transpl 17(Suppl 2): S98-S108.
105. Pruett TL, Tibell A, Alabdulkareem A, Bhandari M, Cronin DC, Dew MA, Dib-Kuri A, Gutmann T, Matas A, McMurdo L, Rahmel A, Rizvi SA, Wright L, Delmonico FL (2006) The ethics statement of the Vancouver Forum on the live lung, liver, pancreas, and intestine donor. Transplantation 81(10): 1386-1387.
106. Grant D, Fisher RA, Abecassis M, McCaughan G, Wright L, Fan ST (2011) Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation? Liver Transpl 17(Suppl 2): S133-S138.
107. Chan SC, Fan ST, Lo CM, Liu CL, Wei WI, Chik BH, Wong J (2008) A decade of right liver adult-to-adult living donor liver transplantation: the recipient mid-term outcomes. Ann Surg 248(3): 411-419.
108. Efimova EA, Glanemann M, Liu L et al (2004) Effects of human hepatocyte growth factor on the proliferation of human hepatocytes and hepatocellular carcinoma cell lines. Eur Surg Res 36: 300.
109. von Schweinitz D, Faundez A, Teichmann B et al (2000) Hepatocyte growth-factor-scatter factor can stimulate post-operative tumor-cell proliferation in childhood hepatoblastoma. Int J Cancer 85: 151.
110. Lo CM, Fan ST, Liu CL, Chan SC, Ng IO, Wong J (2007) Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg 94(1): 78-86.
111. Fisher RA, Kulik LM, Freise CE, Lok AS, Shearon TH, Brown RS Jr, Ghobrial RM, Fair JH, Olthoff KM, Kam I, Berg CL, A2ALL Study Group (2007) Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 7(6): 1601-1608.
112. Bhangui P, Vibert E, Majno P, Salloum C, Andreani P, Zocrato J, Ichai P, Saliba F, Adam R, Castaing D, Azoulay D (2011) Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatology 53(5): 1570-1579.
113. Hwang S, Lee SG, Ahn CS, Kim KH, Moon DB, Ha TY, Park KM, Song GW, Jung DH, Kim BS, Moon KM (2007) Small-sized liver graft does not increase the risk of hepatocellular carcinoma recurrence after living donor liver transplantation. Transplant Proc 39(5): 1526-1529.
114. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M et al (1999) Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397: 530-534.
115. Herman M, Weinstein T, Korzets A, Chagnac A, Ori Y, Zevin D et al (2001) Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 137: 14-20.
116. Schumacher G, Oidtmann M, Rosewicz S, Langrehr J, Jonas S, Mueller AR et al (2002) Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant Proc 34: 1392-1393.
117. Yokoyama I, Carr B, Saitsu H, Iwatsuki S, Starzl TE (1991) Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer 68: 2095-2100.
118. Hui IC, Tung EK, Sze KM, Ching YP, Ng IO (2010) Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma. Liver Int 30: 65-75.
119. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M (2004) mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 10: 8421-8425.
120. Shirouzu Y, Ryschich E, Salnikova O, Kerkadze V, Schmidt J, Engelmann G (2010) Rapamycin inhibits proliferation and migration of hepatoma cells in vitro. J Surg Res 159: 705-713.
121. Schumacher G, Oidtmann M, Rueggeberg A, Jacob D, Jonas S, Langrehr JM et al (2005) Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 11: 1420-1425.
122. Semela D, Piguet AC, Kolev M, Schmitter K, Hlushchuk R, Djonov V et al (2007) Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 46: 840-848.
123. Stippel DL, Kasper HU, Schleimer K, Töx U, Bangard C, Hölscher AH, Beckurts KT (2005) Successful use of sirolimusin a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation. Transplant Proc 37: 2185-2187.
124. Elsharkawi M, Staib L, Henne-Bruns D, Mayer J (2005) Completeremission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation 79: 855-857.
125. Chinnakotla S, Davis GL, Vasani S, Kim P, Tomiyama K, Sanchez E et al (2009) Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 15: 1834-1842.
126. Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, Kam I (2008) Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 14: 633-638.
127. Toso C, Meeberg GA, Bigam DL, Oberholzer J, Shapiro AM, Gutfreund K et al (2007) De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 83: 1162-1168.
128. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM (2010) Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 51: 1237-1243.
129. Liang W, Wang D, Ling X, Cao AA, Kong Y, Shang Y, Guo Z, He X (2011) Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl; doi: 10. 1002/lt. 22441 [Epub ahead of print].
130. Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, de Jong KP, Duvoux C, Kneteman NM, Adam R, Bechstein WO, Becker T, Beckebaum S, Chazouillères O, Cillo U, Colledan M, Fändrich F, Gugenheim J, Hauss JP, Heise M, Hidalgo E, Jamieson N, Königsrainer A, Lamby PE, Lerut JP, Mäkisalo H, Margreiter R, Mazzaferro V, Mutzbauer I, Otto G, Pageaux GP, Pinna AD, Pirenne J, Rizell M, Rossi G, Rostaing L, Roy A, Turrion VS, Schmidt J, Troisi RI, van Hoek B, Valente U, Wolf P, Wolters H, Mirza DF, Scholz T, Steininger R, Soderdahl G, Strasser SI, Jauch KW, Neuhaus P, Schlitt HJ, Geissler EK (2010) A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Canc 10: 190.
131. Regalia E, Fassati LR, Valente U et al (1998) Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat 5: 29-34.
132. Roayaie S, Schwartz JD, Sung MW et al (2004) Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 10: 534-540.
133. Sandroussi C, Guba M, Sandhu L, Dubay D, Ghanekar E, Selzner M et al (2010) Liver transplantation for HCC: characterization of recurrence and outcomes with aggressive multimodal treatment [abstract]. Am J Transplant 10(suppl 4): 452.
134. Taketomi A, Fukuhara T, Morita K, Kayashima H, Ninomiya M, Yamashita Y et al (2010) Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation. Ann Surg Oncol 17: 2283-2289.
135. Marangoni G, Faraj W, Sethi H, Rela M, Muiesan P, Heaton N (2008) Liver resection in liver transplant recipients. Hepatobiliary Pancreat Dis Int 7: 590-594.
136. Kornberg A, Küpper B, Tannapfel A, Katenkamp K, Thrum K, Habrecht O, Wilberg J (2010) Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables. Eur J Surg Oncol 36: 275-280.
137. Chen GH, Fu BS, Yang Y, Cai CJ, Lu MQ, Li H et al (2008) Early liver retransplantation versus late liver retransplantation: analysis of a single-center experience. Chin Med J (Engl) 121: 1992-1996.
138. Yamashiki N, Sugawara Y, Tamura S, Tateishi R, Yoshida H, Kaneko J et al (2010) Postoperative surveillance with monthly serum tumor markers after living-donor liver transplantation for hepatocellular carcinoma. Hepatol Res 40: 278-286.
139. Toso C, Mentha G, Majno P (2011) Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. Am J Transplant 11(10): 2031-2035.
140. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
141. Ohira M, Ohdan H, Mitsuta H et al (2006) Adoptive transfer of TRAIL expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy. Transplantation 82: 1712-1719.